The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01)

The summary for the The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01): This Funding Opportunity Announcement (FOA) encourages preclinical and clinical research that will describe the effect of microbially generated metabolites in cancer prevention/ progression and the molecular mechanisms underlying these effects: proliferative/apoptotic responses, cytokine production, inflammatory and immunomodulatory effects locally and/or distant. This FOA encourages pre-clinical and clinical studies that will describe the variability in the bacterial metabolites production and their contribution to cancer prevention/promotion among various racial and ethnic groups. Due to inconsistent responses to dietary interventions, this research is necessary to identify who might benefit from specific dietary recommend ations and who might be placed at risk. It is important to identify the factors that contribute to differences in response to foods and food components and to identify early markers that will identify those who will receive maximum benefits from dietary change. As these are complex questions this program will facilitate interdisciplinary collaborations among scientists engaged in research in cancer prevention and microbiology, nutrition, cancer cell biology, and cancer disparities. To achieve this goal all applications are encouraged to include multiple Program Director(s)/Principal Investigator(s) with expertise in cancer biology, microbiology, nutrition, analytical chemistry or genetics. Investigations may use either clinical or preclinical approaches. All awardees are expected to attend an annual meeting with NIH personnel to report new findings and coordinate the exchange of new information and methodologies with interested colleagues and to promote collaboration.

Federal Grant Title:	The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-13-159
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.393
CFDA Descriptions:	Cancer Cause and Prevention Research
Current Application Deadline:	Nov 14, 2014
Original Application Deadline:	Nov 14, 2014
Posted Date:	Apr 04, 2013
Creation Date:	Apr 04, 2013
Archive Date:	Dec 15, 2014
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional); • Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required); • National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...; • Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...; • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...; • Pilot Studies in Pancreatic Cancer; • Cancer Prevention Research Small Grant Program; • Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...